Shrey Kanvinde
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shrey Kanvinde has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Chinmay M. Jogdeo
University of Nebraska Medical Center 3 Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, College of Pharmacy Omaha, Nebraska
1 shared publication - David Oupický
University of Nebraska Medical Center
1 shared publication - Ekta Kapoor
University of Nebraska Medical Center 3 Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, College of Pharmacy Omaha, Nebraska
1 shared publication - Kasturi Siddhanta
University of Nebraska Medical Center
1 shared publication - Sudipta Panja
Department of Pharmacology and Experimental Neuroscience University of Nebraska Medical Center 68198-5880. Omaha NE USA
1 shared publication
Latest Publications
- Open Access
- 16 December 2022
- Published by Wiley in Advanced Healthcare Materials
- Vol. 12 (7)
Advances in Lipid‐Based Codelivery Systems for Cancer and Inflammatory Diseases
Combination therapy targeting multiple therapeutic targets is a favorable strategy to achieve better therapeutic outcomes in cancer and inflammatory diseases. Codelivery is a subfield of drug delivery that aims to achieve combined delivery of diverse therapeutic cargoes within the same delivery system, thereby ensuring delivery to the same site and providing an opportunity to tailor the release kinetics as desired. Among the wide range of materials being investigated in the design of codelivery systems, lipids have stood out on account of their low toxicity, biocompatibility, and ease of formulation scale‐up. This review highlights the advances of the last decade in lipid‐based codelivery systems focusing on the codelivery of drug–drug, drug–nucleic acid, nucleic acid–nucleic acid, and protein therapeutic‐based combinations for targeted therapy in cancer and inflammatory diseases.
- 16 December 2022
- Published by Wiley in Advanced Healthcare Materials
- Vol. 12 (7)
Open AccessAdvances in Lipid‐Based Codelivery Systems for Cancer and Inflammatory Diseases
Combination therapy targeting multiple therapeutic targets is a favorable strategy to achieve better therapeutic outcomes in cancer and inflammatory diseases. Codelivery is a subfield of drug delivery that aims to achieve combined delivery of diverse therapeutic cargoes within the same delivery system, thereby ensuring delivery to the same site and providing an opportunity to tailor the release kinetics as desired. Among the wide range of materials being investigated in the design of codelivery systems, lipids have stood out on account of their low toxicity, biocompatibility, and ease of formulation scale‐up. This review highlights the advances of the last decade in lipid‐based codelivery systems focusing on the codelivery of drug–drug, drug–nucleic acid, nucleic acid–nucleic acid, and protein therapeutic‐based combinations for targeted therapy in cancer and inflammatory diseases.